flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 🔴Cardiovascular with by severity of chronic disease in type 2 diabetes: the trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants Semaglutide in CKD - The

Mounjaro (tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that was recently approved by the FDA for the treatment of type 2 diabetes

It was built on all the work that went into liraglutide since the early 90s and incorporated all the clever ideas they had, previously developing longer acting Insulins and things like that

All research must comply with applicable local, state, and federal regulations

Across studies, tirzepatide has produced larger average weight reductions than semaglutide at commonly compared doses

Youll need to ensure that your vial, syringe, and skin are prepped and sanitized before being injected